



**Gerd R Burmester**

**Kontakt**

Gerd R Burmester

## Publikationen (7)

Koehm M, Foldenauer A, Rossmannith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). *J Clin Med* 2022; 11

Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivelles F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2022

Rubbert-Roth A, Furst D, Fiore S, Praetgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. *Arthritis Res Ther* 2022; 24:207.

Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. *Rheumatol Ther* 2021

Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmannith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). *Rheumatology (Oxford)* 2021; 60:5318-5328.

van der Heijde D, Mariette X, Li Z, Koloumas M, Huizinga T, Hetland M, Gottenberg J, Gossec L, Finckh A, Emery P, Müller-Ladner U, Mysler E, da Silva J, Westhovens R, Voshaar M, Takeuchi T, Strangfeld A, Saag K, Ruysen-Witrand A, Rubbert-Roth A, Pope J, Poór G, van Eijk-Hustings Y, Edwards C, Cutolo M, de Wit M, van Vollenhoven R, Sepriano A, McInnes I, Kerschbaumer A, Dougados M, Burmester G, Bijlsma J, Landewé R, Aletaha D, Aringer M, Askling J, Codreanu C, De Cock D, Cardiel M, Caporali R, Buttgereit F, Buch M, den Broeder A, Boers M, Balsa A, Smolen J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020; 79:685-699.

Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. *RMD Open* 2019; 5:e001017.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)